AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Crosses Below 200 Day Moving Average – Time to Sell?

AB Corporate Bond ETF (NASDAQ:EYEG) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $35.48 and traded as low as $34.76. AB Corporate Bond ETF shares last traded at $34.7690, with a volume of 18 shares trading hands.

AB Corporate Bond ETF Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The business has a 50 day moving average price of $35.16 and a two-hundred day moving average price of $35.48. The company has a market cap of $27.82 million, a P/E ratio of -20.70 and a beta of 0.17.

AB Corporate Bond ETF Cuts Dividend

The business also recently disclosed a monthly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Wednesday, July 1st were given a $0.1358 dividend. The ex-dividend date was Wednesday, July 1st. This represents a c) annualized dividend and a yield of 4.7%. AB Corporate Bond ETF’s payout ratio is presently -102.98%.

Institutional Investors Weigh In On AB Corporate Bond ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in AB Corporate Bond ETF during the 4th quarter valued at approximately $34,000. Jane Street Group LLC purchased a new stake in AB Corporate Bond ETF in the 2nd quarter worth approximately $232,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of AB Corporate Bond ETF by 32.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after buying an additional 38,685 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.